<p>Rovin Capital UT ADV 在第二季度收购了强生（NYSE:JNJ - 免费报告）股票的新股份，具体信息在该公司最近向证券交易委员会提交的文件中披露。该基金收购了 1,355 股公司股票，价值约为 207,000 美元。</p>
<ul>
<li>持有评级，高回报？三只可能超出预期的股票</li>
</ul>
<p>其他大型投资者也买卖了该公司的股票。Brighton Jones LLC 在第四季度将其在强生的持仓增加了 13.9%。Brighton Jones LLC 目前拥有 51,876 股公司股票，价值 7,502,000 美元，此前在上个季度又购买了 6,332 股。Wealth Group Ltd. 在第一季度以约 218,000 美元的价格购买了强生的新股份。Smart Money Group LLC 在第一季度将其在强生的持仓增加了 6.5%。Smart Money Group LLC 目前拥有 6,687 股公司股票，价值 1,109,000 美元，此前在上个季度又购买了 407 股。John W. Brooker &amp; Co. CPAs 在第一季度将其在强生的持仓增加了 9.8%。John W. Brooker &amp; Co. CPAs 目前拥有 2,235 股公司股票，价值 371,000 美元，此前在上个季度又购买了 200 股。最后，Slagle Financial LLC 在第一季度将其在强生的持仓增加了 0.6%。Slagle Financial LLC 目前拥有 14,114 股公司股票，价值 2,341,000 美元，此前在上个季度又购买了 86 股。69.55% 的股票由机构投资者持有。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<h2>内部活动</h2>
<p>在其他消息中，执行副总裁 Jennifer L. Taubert 于 9 月 4 日星期四出售了 56,471 股股票。股票以 177.81 美元的平均价格出售，总价值为 10,041,108.51 美元。交易完成后，该执行副总裁直接持有 178,013 股公司股票，价值约为 31,652,491.53 美元。这代表其持仓减少了 24.08%。该出售在与证券交易委员会的法律文件中披露，可以通过此链接访问。公司内部人士持有公司股票的 0.16%。</p>
<h2>强生股票表现</h2>
<ul>
<li>强生的并购策略才是投资者真正关注的故事</li>
</ul>
<p>强生（NYSE:JNJ）股票在星期五开盘价为 186.50 美元。强生的 1 年最低价为 140.68 美元，1 年最高价为 194.48 美元。该公司的市值为 4493.4 亿美元，市盈率为 18.00，市盈率增长比率为 2.19，贝塔值为 0.38。该公司的债务股本比率为 0.50，流动比率为 1.07，速动比率为 0.80。公司的 50 日简单移动平均线为 184.25 美元，200 日简单移动平均线为 168.63 美元。</p>
<p>强生（NYSE:JNJ - 获取免费报告）最近在 8 月 30 日星期三发布了季度财报。公司报告每股收益（EPS）为 2.26 美元。强生的股本回报率为 32.73%，净利润率为 27.26%。该季度的收入为 240.2 亿美元。作为一个整体，研究分析师预测强生在当前财政年度将发布 10.58 的每股收益。</p>
<h2>强生宣布分红</h2>
<ul>
<li>强生股票可以继续上涨，因为战略奏效</li>
</ul>
<p>该公司最近还宣布了季度分红，将于 12 月 9 日星期二支付。11 月 25 日星期二的股东将获得 1.30 美元的分红。这代表年化分红为 5.20 美元，分红收益率为 2.8%。除息日期为 11 月 25 日星期二。强生的分红支付比率（DPR）目前为 50.19%。</p>
<h2>华尔街分析师观点</h2>
<p>几位股票分析师最近对该股票发表了看法。大和证券在 10 月 20 日星期一的研究报告中将强生的股票评级从 “持有” 上调至 “强力买入”。Cowen 在 10 月 14 日星期二的报告中重申了对强生股票的 “买入” 评级。摩根大通在 9 月 16 日星期二的研究报告中将强生的目标价从 185.00 美元上调至 200.00 美元，并给予公司 “中性” 评级。Wall Street Zen 在 9 月 13 日星期六的研究报告中将强生的评级从 “持有” 上调至 “买入”。最后，Guggenheim 在 9 月 23 日星期二的报告中将强生的评级从 “中性” 上调至 “买入”，并将该股票的目标价从 167.00 美元上调至 206.00 美元。三位股票研究分析师对该股票给予了 “强力买入” 评级，十四位给予了 “买入” 评级，九位给予了 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 199.05 美元。</p>
<p><strong>获取我们最新的强生股票分析</strong></p>
<h2>关于强生</h2>
<p>（免费报告）</p>
<p>强生是一家控股公司，专注于医疗领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>三只将受益于军事支出的防御股票</li>
<li>OpenAI 的重组可能会成为有史以来最大的首次公开募股</li>
<li>动荡市场中的资产配置策略</li>
<li>两只美国政府不希望失败的稀土股票</li>
<li>投资石油股票的方式和原因</li>
<li>CrowdStrike 与 CoreWeave 合作，但投资者抛售消息</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在强生吗？</h2>
<p>在考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
<p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>Rovin Capital UT ADV 在第二季度收购了 1,355 股强生（NYSE: JNJ），价值约 207,000 美元。其他投资者，包括 Brighton Jones LLC 和 Smart Money Group LLC，也增加了他们在公司的股份。强生的股票开盘价为 186.50 美元，市值为 4,493.4 亿美元。该公司最近宣布了每季度 1.30 美元的股息，收益率为 2.8%。分析师们已上调了对该股票的评级，目标价格最高达到 200.00 美元</p>

<p>Rovin Capital UT ADV acquired a new stake in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 1,355 shares of the company's stock, valued at approximately $207,000.</p>
<div class="lb-trans"><p>Rovin Capital UT ADV 在第二季度收购了强生（NYSE:JNJ - 免费报告）股票的新股份，具体信息在该公司最近向证券交易委员会提交的文件中披露。该基金收购了 1,355 股公司股票，价值约为 207,000 美元。</p>
</div><ul>
<li>Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations</li>
</ul>
<div class="lb-trans"><ul>
<li>持有评级，高回报？三只可能超出预期的股票</li>
</ul>
</div><p>Other large investors have also bought and sold shares of the company. Brighton Jones LLC grew its position in Johnson &amp; Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Wealth Group Ltd. bought a new position in Johnson &amp; Johnson during the first quarter worth about $218,000. Smart Money Group LLC increased its position in Johnson &amp; Johnson by 6.5% during the first quarter. Smart Money Group LLC now owns 6,687 shares of the company's stock worth $1,109,000 after buying an additional 407 shares during the last quarter. John W. Brooker &amp; Co. CPAs lifted its position in shares of Johnson &amp; Johnson by 9.8% in the first quarter. John W. Brooker &amp; Co. CPAs now owns 2,235 shares of the company's stock valued at $371,000 after buying an additional 200 shares during the last quarter. Finally, Slagle Financial LLC lifted its holdings in Johnson &amp; Johnson by 0.6% during the 1st quarter. Slagle Financial LLC now owns 14,114 shares of the company's stock valued at $2,341,000 after purchasing an additional 86 shares during the last quarter. 69.55% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投资者也买卖了该公司的股票。Brighton Jones LLC 在第四季度将其在强生的持仓增加了 13.9%。Brighton Jones LLC 目前拥有 51,876 股公司股票，价值 7,502,000 美元，此前在上个季度又购买了 6,332 股。Wealth Group Ltd. 在第一季度以约 218,000 美元的价格购买了强生的新股份。Smart Money Group LLC 在第一季度将其在强生的持仓增加了 6.5%。Smart Money Group LLC 目前拥有 6,687 股公司股票，价值 1,109,000 美元，此前在上个季度又购买了 407 股。John W. Brooker &amp; Co. CPAs 在第一季度将其在强生的持仓增加了 9.8%。John W. Brooker &amp; Co. CPAs 目前拥有 2,235 股公司股票，价值 371,000 美元，此前在上个季度又购买了 200 股。最后，Slagle Financial LLC 在第一季度将其在强生的持仓增加了 0.6%。Slagle Financial LLC 目前拥有 14,114 股公司股票，价值 2,341,000 美元，此前在上个季度又购买了 86 股。69.55% 的股票由机构投资者持有。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.16% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，执行副总裁 Jennifer L. Taubert 于 9 月 4 日星期四出售了 56,471 股股票。股票以 177.81 美元的平均价格出售，总价值为 10,041,108.51 美元。交易完成后，该执行副总裁直接持有 178,013 股公司股票，价值约为 31,652,491.53 美元。这代表其持仓减少了 24.08%。该出售在与证券交易委员会的法律文件中披露，可以通过此链接访问。公司内部人士持有公司股票的 0.16%。</p>
</div><h2>Johnson &amp; Johnson Stock Performance</h2>
<div class="lb-trans"><h2>强生股票表现</h2>
</div><ul>
<li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>强生的并购策略才是投资者真正关注的故事</li>
</ul>
</div><p>Shares of NYSE:JNJ opened at $186.50 on Friday. Johnson &amp; Johnson has a 1 year low of $140.68 and a 1 year high of $194.48. The stock has a market capitalization of $449.34 billion, a price-to-earnings ratio of 18.00, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company's 50 day simple moving average is $184.25 and its 200 day simple moving average is $168.63.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ）股票在星期五开盘价为 186.50 美元。强生的 1 年最低价为 140.68 美元，1 年最高价为 194.48 美元。该公司的市值为 4493.4 亿美元，市盈率为 18.00，市盈率增长比率为 2.19，贝塔值为 0.38。该公司的债务股本比率为 0.50，流动比率为 1.07，速动比率为 0.80。公司的 50 日简单移动平均线为 184.25 美元，200 日简单移动平均线为 168.63 美元。</p>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson &amp; Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. As a group, research analysts predict that Johnson &amp; Johnson will post 10.58 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）最近在 8 月 30 日星期三发布了季度财报。公司报告每股收益（EPS）为 2.26 美元。强生的股本回报率为 32.73%，净利润率为 27.26%。该季度的收入为 240.2 亿美元。作为一个整体，研究分析师预测强生在当前财政年度将发布 10.58 的每股收益。</p>
</div><h2>Johnson &amp; Johnson Announces Dividend</h2>
<div class="lb-trans"><h2>强生宣布分红</h2>
</div><ul>
<li>Johnson &amp; Johnson Stock Can Keep Rising as Strategy Pays Off</li>
</ul>
<div class="lb-trans"><ul>
<li>强生股票可以继续上涨，因为战略奏效</li>
</ul>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Tuesday, November 25th. Johnson &amp; Johnson's dividend payout ratio (DPR) is presently 50.19%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度分红，将于 12 月 9 日星期二支付。11 月 25 日星期二的股东将获得 1.30 美元的分红。这代表年化分红为 5.20 美元，分红收益率为 2.8%。除息日期为 11 月 25 日星期二。强生的分红支付比率（DPR）目前为 50.19%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several equities analysts have recently weighed in on the stock. Daiwa America raised shares of Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Monday, October 20th. Cowen reissued a &#34;buy&#34; rating on shares of Johnson &amp; Johnson in a report on Tuesday, October 14th. JPMorgan Chase &amp; Co. upped their target price on Johnson &amp; Johnson from $185.00 to $200.00 and gave the company a &#34;neutral&#34; rating in a research report on Tuesday, September 16th. Wall Street Zen upgraded Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, September 13th. Finally, Guggenheim raised Johnson &amp; Johnson from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and lifted their target price for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $199.05.</p>
<div class="lb-trans"><p>几位股票分析师最近对该股票发表了看法。大和证券在 10 月 20 日星期一的研究报告中将强生的股票评级从 “持有” 上调至 “强力买入”。Cowen 在 10 月 14 日星期二的报告中重申了对强生股票的 “买入” 评级。摩根大通在 9 月 16 日星期二的研究报告中将强生的目标价从 185.00 美元上调至 200.00 美元，并给予公司 “中性” 评级。Wall Street Zen 在 9 月 13 日星期六的研究报告中将强生的评级从 “持有” 上调至 “买入”。最后，Guggenheim 在 9 月 23 日星期二的报告中将强生的评级从 “中性” 上调至 “买入”，并将该股票的目标价从 167.00 美元上调至 206.00 美元。三位股票研究分析师对该股票给予了 “强力买入” 评级，十四位给予了 “买入” 评级，九位给予了 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 199.05 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Johnson &amp; Johnson</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的强生股票分析</strong></p>
</div><h2>About Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>关于强生</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>强生是一家控股公司，专注于医疗领域的产品研究、开发、制造和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>3 Defense Stocks Set to Benefit From Increased Military Spending</li>
<li>OpenAI's Restructuring Sets up What Could Be the Biggest IPO Ever</li>
<li>Asset Allocation Strategies in Volatile Markets</li>
<li>2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>CrowdStrike Partners With CoreWeave But Investors Sell the News</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>三只将受益于军事支出的防御股票</li>
<li>OpenAI 的重组可能会成为有史以来最大的首次公开募股</li>
<li>动荡市场中的资产配置策略</li>
<li>两只美国政府不希望失败的稀土股票</li>
<li>投资石油股票的方式和原因</li>
<li>CrowdStrike 与 CoreWeave 合作，但投资者抛售消息</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Rovin Capital UT ADV 购入了 1,355 股强生公司$JNJ 的股票